Treatment of septic shock and use of drotrecogin alfa (activated) in children

References

• Watson RS, Carcillo JA, Linde-Zwirble WT et al. The epidemiology of severe sepsis in children in the United States. Am. J. Respir. Crit. Care Med.167, 695–701 (2003).
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C. Epidemiology of severe sepsis. Presse Med.35(3 Pt 2), 513–520 (2006).
   PubMedGoogle Scholar
• Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit. Care Med.29(7 Suppl.), S21–S27 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson MR, Blumer JL. Advances in the therapy for sepsis in children. Pediatr. Clin. North Am.44, 179–205 (1997).
   PubMedGoogle Scholar
• Butt W. Septic shock. Pediatr. Clin. North Am.48, 601–625 (2001).
   PubMedGoogle Scholar
• Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler. Thromb. Vasc. Biol.20, 2511–2518 (2000).
   PubMed Web of Science ®Google Scholar
• Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit. Care Med.29(7 Suppl.), S62–S67 (2001).
   PubMedGoogle Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med.29, 1303–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma VK, Dellinger RP. Treatment options for severe sepsis and septic shock. Expert Rev. Anti Infect. Ther.4, 395–403 (2006).
   PubMedGoogle Scholar
• Girbes AR, Beishuizen A, Strack van Schijndel RJ. Pharmacological treatment of sepsis. Fundam. Clin. Pharmacol.22, 355–361 (2008).
   PubMedGoogle Scholar
• Raghavan M, Marik PE. Management of sepsis during the early ‘golden hours’. J. Emerg. Med.31, 185–199 (2006).
   PubMedGoogle Scholar
• Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med.36, 296–327 (2008).
   PubMed Web of Science ®Google Scholar
• Rivers EP, Coba V, Whitmill M. Early goal-directed therapy in severe sepsis and septic shock: a contemporary review of the literature. Curr. Opin. Anaesthesiol.21, 128–140 (2008).
   PubMed Web of Science ®Google Scholar
• Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest122, 262–268 (2002).
   PubMed Web of Science ®Google Scholar
• Oliveira CF, Nogueira de Sá FR, Oliveira DS et al. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world. Pediatr. Emerg. Care24, 810–815 (2008).
   PubMedGoogle Scholar
• Brierley J, Carcillo JA, Choong K et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit. Care Med.37, 666–688 (2009).
   PubMed Web of Science ®Google Scholar
• De Backer D, Creteur J, Silva E et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit. Care Med.31, 1659–1667 (2003).
   PubMed Web of Science ®Google Scholar
• Ruggiero MS. Effects of vasopressin in septic shock. AACN Adv. Crit. Care19, 281–287 (2008).
   PubMedGoogle Scholar
• Choong K, Kissoon N. Vasopressin in pediatric shock and cardiac arrest. Pediatr. Crit. Care Med.9, 372–379 (2008).
   PubMed Web of Science ®Google Scholar
• Sevransky JE, Levy MM, Marini JJ. Mechanical ventilation in sepsis-induced acute lung injury/acute respiratory distress syndrome: an evidence-based review. Crit. Care Med.32(11 Suppl.), S548–S553 (2004).
   PubMed Web of Science ®Google Scholar
• The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med.342, 1301–1308 (2000).
   PubMed Web of Science ®Google Scholar
• Marraro GA. Protective lung strategies during artificial ventilation in children. Paediatr. Anaesth.15, 630–637 (2005).
   PubMedGoogle Scholar
• NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med.360, 1283–1297 (2009).
   PubMed Web of Science ®Google Scholar
• Fahy BG, Sheehy AM, Coursin DB. Glucose control in the intensive care unit. Crit. Care Med.37, 1769–1776 (2009).
   PubMed Web of Science ®Google Scholar
• Valoor HT, Singhi S, Jayashree M. Low-dose hydrocortisone in pediatric septic shock: an exploratory study in a third world setting. Pediatr. Crit. Care Med.10, 121–125 (2009).
   PubMedGoogle Scholar
• Nadel S, Goldstein B, Williams MD et al. Researching Severe Sepsis and Organ Dysfunction in Children: a Global Perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre Phase III randomised controlled trial. Lancet369, 836–843 (2007).
   PubMed Web of Science ®Google Scholar
• Barton P, Kalil AC, Nadel S et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics113(1 Pt 1), 7–17 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein B, Nadel S, Peters M et al. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr. Crit. Care Med.7, 200–211 (2006).
   PubMed Web of Science ®Google Scholar
• De Backer D. Benefit–risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. Drug Saf.30, 995–1010 (2007).
   PubMedGoogle Scholar
• Dhainaut JF, Antonelli M, Wright P et al. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med.35, 1187–1195 (2009).
   PubMedGoogle Scholar
• Martin G, Brunkhorst FM, Janes J et al. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit. Care13, R103 (2009).
   PubMedGoogle Scholar
• Lorenz BD, Smith TD, Laessig K et al. Recombinant activated protein C and risk of bleeding. Crit. Care Med.37, 2141–2142 (2009).
   PubMedGoogle Scholar
• Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit. Care Clin.24(3 Suppl.), S1–S47 (2008).
   PubMedGoogle Scholar
• Balk RA. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations. Dis. Mon.50, 168–213 (2004).
   PubMed Web of Science ®Google Scholar
• Ahishakiye D, Lorent S, De Backer D et al. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course? J. Crit. Care (2009) (Epub ahead of print).
   PubMedGoogle Scholar